What we do

Biotica Bio delivers evidence-based target and strategy support for life sciences startups and investment firms. Every deliverable is grounded in the Open Targets Platform, so narratives are traceable to the same public evidence that industry uses—and can be re-run or updated as data changes.

Services

• Target and indication assessment — Comprehensive, oncology-style assessments (biology, disease associations, druggability, safety, prioritisation) from a single Open Targets query, interpreted for strategy and R&D.
• Due diligence support — Evidence-led review of targets and pipelines for investors: reproducible, auditable, and aligned with public data releases.
• Pipeline and portfolio review — Prioritisation and landscape context so you can focus resources and narrative on the strongest opportunities.
• Executive summaries and one-pagers — Board- or partner-ready outputs when you need brevity without losing rigour.

Engagement

All engagements are scoped and confidential. We do not invest, so there is no conflict of interest.

Our assessments are for strategic and due-diligence use only; they do not constitute regulatory, medical, or investment advice.